Saturday, 21 November 2026
IHSG
0
0 (0%)

Latest Research

XL Smart (EXCL IJ): Optimization in sight
2026-11-20 10:38:31

 XL Smart (EXCL IJ)
BUY / TP: IDR:2,820 (+70.4%)
Analyst: Chandra Pasaribu

Optimization in sight
• Operation numbers were in line
• Operational numbers show positive traction
• Another round of guidance upgrades
• Re-iterate BUY

Read More
Indofood Sukses Makmur (INDF IJ): Robust growth in 9M26, agribusiness and distribution carry margin
2026-11-19 15:28:32

Indofood Sukses Makmur (INDF IJ)
BUY / TP: IDR:9,200 (+28.7%)
Analyst: Erdji Herlando

Robust growth in 9M26, agribusiness and distribution carry margin
• Robust sales growth from all businesses, led by CBP
• Agribusiness and distribution offset margin pressure from CBP and flour business
• Share buyback
• Re-iterate BUY with new TP

Read More
Indofood CBP Sukses Makmur (ICBP IJ): Volume-led beat – FX loss on USD bonds weighs on results
2026-11-18 11:24:53

Indofood CBP Sukses Makmur (ICBP IJ)
BUY / TP: IDR:9,500 (+37.2%)
Analyst: Erdji Herlando

Volume-led beat – FX loss on USD bonds weighs on results
• Growth is volume-led
• Raw material costs weigh on gross margin
• Share buyback
• Re-iterate BUY with new TP of IDR9,500 (US$0.52)

Read More
Erajaya Swasembada (ERAA IJ): Resilient growth, continued expansion
2026-11-18 09:58:34

Erajaya Swasembada (ERAA IJ)
BUY / TP: IDR:810 (+58.8%)
Analyst: Erdji Herlando

Resilient growth, continued expansion
• Cellular phones keep growing, with the iPhone 18 as the next catalyst
• Active & Lifestyle (A&L) continues to expand
• Erablue keeps gaining share in a fragmented market
• Food & Nourishment (F&N) and Accessories & Others (AC&O) sustained the base
• We re-initiate coverage and re-iterate BUY with the raised target price (TP) of IDR810 (US$0.03), which offers a massive upside of +58.8% upside

Read More
Bank Mandiri (BMRI IJ): Top-line stabilizes
2026-11-16 11:23:50

Bank Mandiri (BMRI IJ)
BUY / TP: IDR:5,500 (+41.4%)
Analyst: Yap Swie Cu

Top-line stabilizes
• Lending growth and repricing offset funding cost pressure
• Solid fee-income further supported earnings
• Credit cost remained low, strong core earnings provide room to build a stronger buffer
• Re-iterate BUY on the bank’s resilient earnings outlook and its undemanding valuation

Read More
Kalbe Farma (KLBF IJ): Volume-led growth, pressured margin
2026-11-11 16:08:01

Kalbe Farma (KLBF IJ)
Not rated
Analyst: Erdji Herlando

Volume-led growth, pressured margin
• Growth is volume-led but slowed in 3Q26
• Top-line strategy and run-rate remain intact, but margin stays under pressure through FY2027
• Earnings remain sound, but share price dilutes

Read More

Yuanta Sekuritas Indonesia